PRTC vs. ARQT, GLPG, INDV, AKRO, DYN, IMCR, EVO, TVTX, VIR, and GPCR
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Arcutis Biotherapeutics (ARQT), Galapagos (GLPG), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Travere Therapeutics (TVTX), Vir Biotechnology (VIR), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
PureTech Health vs.
PureTech Health (NASDAQ:PRTC) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations.
PureTech Health has higher earnings, but lower revenue than Arcutis Biotherapeutics.
PureTech Health has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
PureTech Health presently has a consensus price target of $45.00, suggesting a potential upside of 149.45%. Arcutis Biotherapeutics has a consensus price target of $16.60, suggesting a potential upside of 30.91%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Arcutis Biotherapeutics.
Arcutis Biotherapeutics received 53 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 65.26% of users gave Arcutis Biotherapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote.
0.0% of PureTech Health shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 1 mentions for PureTech Health. Arcutis Biotherapeutics' average media sentiment score of 0.62 beat PureTech Health's score of 0.47 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
PureTech Health has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. PureTech Health's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
Summary
PureTech Health beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (NASDAQ:PRTC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free PRTC Stock Alerts